Skip to content
HowShorted

TherapeuticsMD, Inc. short interest in 2018

In 2018, TherapeuticsMD, Inc.'s disclosed short interest ran from 24.66% of shares outstanding on 12 Jan 2018 to 29.49% on 31 Dec 2018, a change of +4.83 percentage points. The year's high was 32.12% on 31 Oct 2018 and its low 24.22% on 31 Jan 2018, averaging 27.75% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 43.47 days on 13 Jul 2018. Full history: TherapeuticsMD, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for TherapeuticsMD, Inc. in 2018

2018 in figures

Start of year
24.66% (12 Jan 2018)
End of year
29.49% (31 Dec 2018)
Change
+4.83 pp
High
32.12% (31 Oct 2018)
Low
24.22% (31 Jan 2018)
Average
27.75%
Highest days to cover
43.47 (13 Jul 2018)
SEC filings marked
8

Every report in 2018

TherapeuticsMD, Inc. short interest in 2018
SettlementShort interestDays to coverFilings since previous
12 Jan 201824.66%32.80
31 Jan 201824.22%30.53
15 Feb 201825.22%26.58
28 Feb 201825.90%26.97results (8-K), 10-K filed
15 Mar 201826.77%28.68
29 Mar 201826.57%29.85
13 Apr 201827.04%25.11
30 Apr 201826.56%31.31
15 May 201825.44%20.02results (8-K), 10-Q filed
31 May 201827.40%11.75
15 Jun 201827.55%11.77
29 Jun 201827.27%22.88
13 Jul 201827.45%43.47
31 Jul 201826.85%29.4410-Q filed, results (8-K)
15 Aug 201827.71%20.18
31 Aug 201828.41%27.15
14 Sep 201828.93%28.89
28 Sep 201830.22%27.62
15 Oct 201830.77%20.88
31 Oct 201832.12%18.89
15 Nov 201829.04%21.44results (8-K), 10-Q filed
30 Nov 201830.65%30.65
14 Dec 201829.76%22.77
31 Dec 201829.49%16.30

See also: TherapeuticsMD, Inc.'s full history · most shorted US stocks of 2018 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.